To further clarify the risk factors of high alert medications in medical institutions, and promote the standardization of risk management of high alert medications, the Guidelines for Risk Management of High Alert Medications in Chinese Medical Institutions were jointly formulated by the Pharmaceutical Service Professional Committee of China Medical Education Association, Pharmaceutical Therapeutics Professional Committee of Henan Pharmaceutical Association, Institute of Hospital Management, Wuhan University and Zhengzhou Pharmaceutical Management and Pharmacotherapeutics Committee. The guideline would be developed based on the latest definition of Institution of Medicine (IOM) about clinical practice guideline (CPG), World Health Orgnization (WHO) handbook, Appraisal of Guidelines Research and Evaluation (AGREE Ⅱ), and the Reporting Items for Practice Guidelines in Healthcare (RIGHT). The background, applicable population, guideline formulation committee, determination of clinical problems and outcome indicators, evidence retrieval strategy and formation of recommendation opinions could be reported in this protocol.

1.邱苑华, 主编. 现代项目风险管理方法与实践[M]. 北京: 科学出版社, 2003: 1-12.

2.唐蓉蓉. 药品安全风险管理研究——以宁波市为例[D].浙江宁波: 宁波大学, 2017.

3.Institute for Safe Medication Practices. High-alert medications in community/ambulatory care settings[EB/OL].

(2021-09-30) [2022-04-20]. https://www.ismp.org/resources/high-alert-medication-listonly-effective-when-combined-risk-reduction-strategies.

4.World Health Organization. Medication without harm[EB/OL]. (2017-03-29) [2021-07-30]. https://www.who.int/initiatives/medication-without-harm.

5.World Health Organization. Global patient safety action plan 2021-2030[EB/OL]. (2021-08-03) [2022-07-13].https://www.who.int/publications/i/item/9789240032705.

6.国家卫生健康委员会办公厅. 关于进一步加强患者安全管理工作的通知[EB/0L]. (2018-04-19) [2022-07-13]. https://www.gov.cn/zhengce/zhengceku/2018-12/31/content_5435146.htm.

7.国家卫生健康委, 教育部, 财政部, 等. 关于印发加强医疗机构药事管理促进合理用药的意见的通知[EB/OL]. (2020-02-21) [2022-07-13]. https://www.gov.cn/gongbao/content/2020/content_5522549.htm.

8.中国医药教育协会高警示药品管理专业委员会, 中国药学会医院药学专业委员会, 中国药理学会药源性疾病学专业委员会. 中国高警示药品临床使用与管理专家共识(2017)[J]. 药物不良反应杂志, 2017, 19(6): 409-413. DOI: 10.3760/cma.j.issn.1008-5734.2017.06.003.

9.张海. 妇幼专科医院高警示药品安全管理与使用专家共识[J]. 药学服务与研究, 2020, 20(4): 255-260. [Zhang H. Expert consensus on safety management and use of high-alert medications in maternal and child hospitals[J].Pharmaceutical Care and Research, 2020, 20(4): 255-260.] DOI: 10.5428/pcar20200405.

10.Institute of Medicine. Clinical practice guidelines we can trust[M]. Washington DC: the National Academies Press, 2011.

11.World Health Organization. Handbook for guideline development 2014[DB/OL]. (2014) [2022-05-27]. https:// apps.who.Int/iris /handle/10665/145714.

12.Brouwers MC, Kerkvliet K, Spithoff K, et al. The AGREE Reporting Checklist: a tool to improve reporting of clinical practice guidelines[J]. BMJ, 2016, 352: i1152. DOI: 10.1136/ bmj. i1152.

13.Chen Y, Yang K, Marušic A, et al. A reporting tool for practice guidelines in health care: the RIGHT Statement[J]. Ann Intern Med, 2017, 166(2): 128-132. DOI: 10.7326/M16-1565.

14.Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non randomised studies of healthcare interventions, or both[J]. BMJ, 2017, 358: j4008. DOI: 10.1136/bmj.j4008.

15.解染, 陈耀龙, 陈昊, 等. 循证指南制定中患者价值观和偏好的研究方法[J]. 中国循证医学杂志, 2015, 15(5): 586-591. [Xie R, Chen YL, Chen H, et al. Method of patient values and preferences research in development of clinical practice guidelines[J]. Chinese Journal of Evidence-Based Medicine, 2015, 15(5): 586-591.] DOI: 10.7507/1672-2531.20150097.

16.王明辉, 张菁, 曾宪涛, 等. 临床实践指南制订方法—患者的价值观和意愿[J]. 中国循证心血管医学杂志, 2018, 10(10): 1153-1156, 1161. [Wang MH, Zhang J, Zeng XT, et al. Methodological series for clinical practice guidelines: patient values and preferences[J].Chinese Journal of Evidence-Bases Cardiovascular Medicine, 2018, 10(10): 1153-1156, 1161.] DOI: 10.3969/j.issn.1674-4055.2018.10.01.